IL165285A0 - Compositions and methods for treating diabetes - Google Patents
Compositions and methods for treating diabetesInfo
- Publication number
- IL165285A0 IL165285A0 IL16528503A IL16528503A IL165285A0 IL 165285 A0 IL165285 A0 IL 165285A0 IL 16528503 A IL16528503 A IL 16528503A IL 16528503 A IL16528503 A IL 16528503A IL 165285 A0 IL165285 A0 IL 165285A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- treating diabetes
- gastrin
- treating
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 2
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
- 102100021022 Gastrin Human genes 0.000 abstract 1
- 102000052874 Gastrin receptors Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000009707 neogenesis Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38703202P | 2002-06-07 | 2002-06-07 | |
| US43059002P | 2002-12-03 | 2002-12-03 | |
| PCT/US2003/018377 WO2003103701A1 (en) | 2002-06-07 | 2003-06-09 | Compositions and methods for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165285A0 true IL165285A0 (en) | 2005-12-18 |
Family
ID=29739925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16528503A IL165285A0 (en) | 2002-06-07 | 2003-06-09 | Compositions and methods for treating diabetes |
| IL165285A IL165285A (en) | 2002-06-07 | 2004-11-18 | Compositions for treating diabetes, kits comprising such compositions and other uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165285A IL165285A (en) | 2002-06-07 | 2004-11-18 | Compositions for treating diabetes, kits comprising such compositions and other uses |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7560425B2 (https=) |
| EP (1) | EP1511509B1 (https=) |
| JP (1) | JP2005533775A (https=) |
| KR (1) | KR20050048542A (https=) |
| CN (1) | CN1671407B (https=) |
| AT (2) | ATE445407T1 (https=) |
| AU (1) | AU2003243501A1 (https=) |
| CA (1) | CA2486584A1 (https=) |
| DE (2) | DE60329724D1 (https=) |
| ES (1) | ES2334268T3 (https=) |
| IL (2) | IL165285A0 (https=) |
| WO (1) | WO2003103701A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| CN1486204A (zh) | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| IL165242A0 (en) * | 2002-05-24 | 2005-12-18 | Waratah Pharmaceuticals Inc | Treatment for diabetes |
| EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| DE60329724D1 (de) | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| DE602004004520T2 (de) * | 2003-04-22 | 2007-11-08 | Wyeth | Antineoplastische zusammensetzungen |
| US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
| WO2005072045A2 (en) * | 2004-01-30 | 2005-08-11 | Waratah Pharmaceuticals, Inc. | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
| EP1765873A4 (en) * | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| RU2403800C2 (ru) * | 2004-12-30 | 2010-11-20 | Хилл`С Пет Ньютришн, Инк. | Композиция для кошачьего потребления |
| CN101365476A (zh) * | 2005-10-07 | 2009-02-11 | 瓦拉塔药品公司 | Dpp-iv抑制剂和胃泌素化合物的联合使用 |
| US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7425542B2 (en) * | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| US20090326193A1 (en) * | 2006-06-23 | 2009-12-31 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) * | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8084022B2 (en) * | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| CN101489578A (zh) * | 2006-07-14 | 2009-07-22 | 浦项工科大学校产学协力团 | 表皮生长因子增加胰岛素分泌并降低血糖 |
| US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| JP2011529078A (ja) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自己免疫疾患を治療および予防するための方法および組成物 |
| US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
| WO2010081015A1 (en) * | 2009-01-09 | 2010-07-15 | The Regents Of The University Of California | Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening |
| ES2683902T3 (es) | 2011-06-14 | 2018-09-28 | Hale Biopharma Ventures, Llc | Administración de benzodiacepina |
| WO2013020069A1 (en) * | 2011-08-03 | 2013-02-07 | Ma Zhongmin | Treatment of type 2 diabetes with fty720 |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| BR112014010532A2 (pt) | 2011-11-03 | 2017-04-18 | Tolera Therapeutics Inc | anticorpo e métodos para inibição seletiva de respostas de célula-t |
| WO2014138003A1 (en) * | 2013-03-04 | 2014-09-12 | Neuralstem, Inc. | Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders |
| US11116777B2 (en) | 2015-11-10 | 2021-09-14 | City Of Hope | Conditioning regimens and methods for inducing mixed chimerism |
| WO2017116569A1 (en) * | 2015-12-31 | 2017-07-06 | City Of Hope | Methods for treating diabetes |
| US20210355448A1 (en) * | 2017-06-26 | 2021-11-18 | City Of Hope | Methods of islet cell culture |
| IL280198B2 (en) * | 2018-07-18 | 2026-01-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| JP2024521399A (ja) | 2021-06-10 | 2024-05-31 | ニューレリス、インク． | 小児患者における発作性障害を治療するための組成物および方法 |
| EP4376866A4 (en) * | 2021-06-10 | 2025-10-08 | Fouad Kandeel | COMPOSITIONS AND METHODS FOR ISLET OF LANGERHANS TRANSPLANTS |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101353A0 (en) | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5885956A (en) | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
| US6558952B1 (en) | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| EP1132091A1 (en) * | 1994-01-24 | 2001-09-12 | The General Hospital Corporation | Treatment for diabetes |
| US5624895A (en) | 1994-02-18 | 1997-04-29 | Georgetown University Medical Center | Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration |
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US20040037818A1 (en) | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| ATE251465T1 (de) | 1998-07-31 | 2003-10-15 | Novo Nordisk As | In-vitro stimulation von beta zellen vermehrung |
| US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
| KR20080067009A (ko) | 2000-03-31 | 2008-07-17 | 프로시디온 리미티드 | 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물 |
| CN1486204A (zh) | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| IL165242A0 (en) | 2002-05-24 | 2005-12-18 | Waratah Pharmaceuticals Inc | Treatment for diabetes |
| EP1837031B1 (en) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| DE60329724D1 (de) | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
| AU2003283004A1 (en) | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
| US20040229810A1 (en) | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| WO2004096853A1 (en) | 2003-04-30 | 2004-11-11 | Waratah Pharmaceuticals, Inc. | Combined use of keratinocyte growth factor agonists and gastrin compounds |
| CN1829528A (zh) | 2003-05-27 | 2006-09-06 | 瓦拉塔药品公司 | 包含胃泌素化合物的组合物及其在糖尿病中的应用 |
| WO2005072045A2 (en) | 2004-01-30 | 2005-08-11 | Waratah Pharmaceuticals, Inc. | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
| EP1765873A4 (en) | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES |
| CN101365476A (zh) | 2005-10-07 | 2009-02-11 | 瓦拉塔药品公司 | Dpp-iv抑制剂和胃泌素化合物的联合使用 |
| EP1971363A1 (en) | 2005-12-02 | 2008-09-24 | Waratah Pharmaceuticals, Inc. | Combination treatments with gastrin agonists for diabetes and related diseases |
| WO2007095737A1 (en) | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
-
2003
- 2003-06-09 DE DE60329724T patent/DE60329724D1/de not_active Expired - Lifetime
- 2003-06-09 AT AT07010865T patent/ATE445407T1/de not_active IP Right Cessation
- 2003-06-09 US US10/517,135 patent/US7560425B2/en not_active Expired - Fee Related
- 2003-06-09 IL IL16528503A patent/IL165285A0/xx unknown
- 2003-06-09 CA CA002486584A patent/CA2486584A1/en not_active Abandoned
- 2003-06-09 AT AT03757483T patent/ATE375166T1/de not_active IP Right Cessation
- 2003-06-09 EP EP03757483A patent/EP1511509B1/en not_active Expired - Lifetime
- 2003-06-09 DE DE60316798T patent/DE60316798T2/de not_active Expired - Lifetime
- 2003-06-09 WO PCT/US2003/018377 patent/WO2003103701A1/en not_active Ceased
- 2003-06-09 KR KR1020047019788A patent/KR20050048542A/ko not_active Ceased
- 2003-06-09 CN CN038185261A patent/CN1671407B/zh not_active Expired - Fee Related
- 2003-06-09 JP JP2004510820A patent/JP2005533775A/ja active Pending
- 2003-06-09 AU AU2003243501A patent/AU2003243501A1/en not_active Abandoned
- 2003-06-09 US US10/457,126 patent/US20040023885A1/en not_active Abandoned
- 2003-06-09 ES ES07010865T patent/ES2334268T3/es not_active Expired - Lifetime
-
2004
- 2004-11-18 IL IL165285A patent/IL165285A/en not_active IP Right Cessation
-
2009
- 2009-04-08 US US12/420,212 patent/US20090269337A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003243501A1 (en) | 2003-12-22 |
| JP2005533775A (ja) | 2005-11-10 |
| EP1511509A4 (en) | 2005-04-27 |
| ATE375166T1 (de) | 2007-10-15 |
| DE60329724D1 (de) | 2009-11-26 |
| IL165285A (en) | 2010-04-29 |
| CA2486584A1 (en) | 2003-12-18 |
| CN1671407B (zh) | 2010-05-26 |
| US20090269337A1 (en) | 2009-10-29 |
| WO2003103701A1 (en) | 2003-12-18 |
| EP1511509A1 (en) | 2005-03-09 |
| ATE445407T1 (de) | 2009-10-15 |
| EP1511509B1 (en) | 2007-10-10 |
| KR20050048542A (ko) | 2005-05-24 |
| ES2334268T3 (es) | 2010-03-08 |
| US7560425B2 (en) | 2009-07-14 |
| US20040023885A1 (en) | 2004-02-05 |
| CN1671407A (zh) | 2005-09-21 |
| DE60316798D1 (de) | 2007-11-22 |
| US20060183674A1 (en) | 2006-08-17 |
| DE60316798T2 (de) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165285A0 (en) | Compositions and methods for treating diabetes | |
| WO2004037195A3 (en) | Treatment of diabetes | |
| IL156828A0 (en) | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes | |
| MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
| CA101579S (en) | Keypad for a handset | |
| NO20013451L (no) | 1-Heterocyklus-substituerte diarylaminer | |
| AU2003209304A1 (en) | Apparatus and methods for conduits and materials | |
| CA102338S (en) | Keypad for a handset | |
| CA102893S (en) | Keypad for a handset | |
| DE60124710D1 (de) | Analoge des glucagon ähnlichen peptid-1 | |
| MY139049A (en) | Formulations comprising ecteinascidin and a disaccharide | |
| MXPA05010582A (es) | Combinaciones antineoplasicas. | |
| CA102464S (en) | Keypad for a handset | |
| TNSN05046A1 (en) | Method of preparing dry powder inhalation compositions | |
| CA102330S (en) | Front cover for a handset | |
| WO2004058153A9 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
| TW200616639A (en) | Methods for treating a mammal before, during and after cardiac arrest | |
| CA102901S (en) | Front cover for a handset | |
| EP1511506A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING, TREATING AND DIAGNOSING DIABETES | |
| CA102846S (en) | Front cover for a handset | |
| CA102847S (en) | Combined keypad and frame for handset | |
| WO2004035033A3 (en) | Clofarabine and camptothecin chemotherapy combination | |
| CA102197S (en) | Front cover for a handset | |
| AU2002320653B2 (en) | Stent graft with branch leg | |
| UA70251A (en) | Method for treating newly diagnosed patients with tuberculosis of urinary system |